패혈증 진단 시장 예측(-2031년) : 제품별, 기술별, 방법별, 병원체 유형별, 검사 유형별, 시료 유형별, 플렉스별, 임상 활용/관리 경로별, 최종사용자별, 지역별

The sepsis diagnostics market is projected to reach USD 1.22 billion by 2031, up from USD 0.83 billion in 2026, at a CAGR of 7.9%. The global sepsis diagnostics market is expected to grow steadily over the forecast period, driven by the rising burden of sepsis and bloodstream infections, increasing ICU admissions, growing demand for rapid pathogen identification, and rising adoption of molecular diagnostics, automated microbiology platforms, immunoassays, and biomarker-based testing.

Market growth is further supported by the increasing focus on antimicrobial stewardship programs, the need to reduce diagnostic turnaround time, and the adoption of automated diagnostic workflows in hospital and reference laboratories. However, the high cost of advanced molecular diagnostic platforms, limited reimbursement for novel diagnostic technologies, the clinical complexity of sepsis presentation, workflow integration challenges, and a shortage of trained laboratory personnel are expected to restrain market growth to some extent.

"Assays & reagent kits accounted for the largest share of the sepsis diagnostics market, by product, in 2025."

By product, the sepsis diagnostics market is segmented into blood culture media, assays & reagent kits, instruments, and software. In 2025, assays & reagent kits accounted for the largest market share, driven by their recurring use in blood culture testing, immunoassays, molecular diagnostics, antimicrobial susceptibility testing, and biomarker-based sepsis assessment. Rising demand for pathogen detection kits, PCR-based reagents, syndromic testing panels, inflammatory biomarker assays, and sepsis-related consumables continues to support this segment's dominance. Additionally, the growing adoption of automated and molecular testing platforms across hospitals and reference laboratories is further strengthening demand for assays and reagent kits.

"Blood culture/microbiology testing accounted for the largest share of the sepsis diagnostics market, by technology, in 2025."

By technology, the global sepsis diagnostics market is segmented into blood culture/microbiology testing, immunoassays, molecular diagnostics, flow cytometry, mass spectrometry, and clinical chemistry & blood gas analysis. In 2025, blood culture/microbiology testing accounted for the largest share, reflecting its established role as the standard diagnostic approach for detecting bloodstream infections and supporting antimicrobial susceptibility testing. These technologies are widely used in hospital microbiology laboratories for pathogen detection, organism identification, and therapy guidance. However, molecular diagnostics is expected to grow faster over the forecast period, supported by increasing adoption of PCR/RT-PCR, multiplex PCR panels, microarrays, FISH/PNA-FISH, DNA sequencing, NGS, LAMP, and TMA-based methods for rapid pathogen and resistance marker detection.

"The Asia Pacific region is projected to grow at the highest CAGR in the sepsis diagnostics market from 2026 to 2031."

The sepsis diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, the Asia Pacific region is projected to have the highest CAGR, driven by the rising burden of infectious diseases and bloodstream infections, expanding hospital and ICU infrastructure, rising healthcare expenditure, and growing adoption of automated microbiology and molecular diagnostic platforms. Growth is further supported by improving laboratory capacity, greater awareness of sepsis management, rising demand for rapid diagnostics, and large patient populations across China, Japan, India, South Korea, Australia, and Southeast Asia.

List of Companies Profiled in the Report

• Biomerieux
• Becton Dickinson and Company
• Danaher Corporation
• Diasorin S.P.A (Luminex)
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific, Inc
• Bruker Corporation
• Abbott Laboratories
• Sysmex Corporation
• Siemens Healthineers
• Qiagen
• Quidelortho Corporation
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

Research Coverage

This research report categorizes the sepsis diagnostics market by product, technology, method, pathogen type, test type, sample type, complexity, clinical utility/management pathway, end user, and region. The scope of the report covers detailed information on the major factors influencing the market, including drivers, restraints, opportunities, and challenges. It includes a detailed analysis of key industry players, providing insights into their business overview, product portfolio, key strategies such as product launches, regulatory approvals, collaborations, partnerships, acquisitions, and expansions, as well as recent developments associated with the sepsis diagnostics market. This report also covers a competitive analysis of leading players and emerging companies in the sepsis diagnostics ecosystem.

Key Benefits of Buying the Report

The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall sepsis diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses effectively and develop suitable go-to-market strategies. The report will enable stakeholders to understand the market pulse and provide information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following points:

• Analysis of key drivers, including the high incidence of sepsis and bloodstream infections, growing adoption of rapid molecular and syndromic diagnostics, increasing focus on antimicrobial stewardship, and expansion of biomarker-based testing; restraints, including the high cost of advanced molecular diagnostic platforms and limited reimbursement for novel diagnostic technologies; opportunities, including AI-enabled sepsis diagnosis, clinical decision support, next-generation host-response biomarkers, rapid POC testing, and decentralized testing; and challenges, including clinical complexity, heterogeneous sepsis presentation, integration into hospital workflows, and a shortage of trained laboratory personnel
• Product Development/Innovation: Detailed insights into newly launched and emerging sepsis diagnostics products, including automated blood culture systems, molecular diagnostic panels, syndromic testing platforms, immunoassays, biomarker-based tests, mass spectrometry-based microbial identification platforms, antimicrobial susceptibility testing solutions, and AI-enabled clinical decision support tools
• Market Development: Comprehensive information about lucrative markets - the report analyzes the sepsis diagnostics market across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with detailed assessment of major country-level opportunities and adoption trends
• Market Diversification: Comprehensive information on product portfolios, technological developments, regulatory approvals, collaborations, partnerships, acquisitions, geographic expansions, and investments in the sepsis diagnostics market

Competitive Assessment: In-depth assessment of market shares, growth strategies, technological capabilities, diagnostic platforms, service offerings, and competitive positioning of leading players, including bioMerieux SA, Becton, Dickinson and Company, Danaher Corporation, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Bruker Corporation, and DiaSorin S.p.A., among others

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 SEPSIS DIAGNOSTICS MARKET OVERVIEW
• 3.2 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2026 VS. 2031
• 3.3 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031
• 3.4 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2026 VS. 2031
• 3.5 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2026 VS. 2031
• 3.6 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2026 VS. 2031
• 3.7 SEPSIS DIAGNOSTICS MARKET, SAMPLE TYPE, 2026 VS. 2031
• 3.8 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2026 VS. 2031
• 3.9 SEPSIS DIAGNOSTICS MARKET, CLINICAL UTILITY/MANAGEMENT PATHWAY, 2026 VS. 2031
• 3.10 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031
• 3.11 SEPSIS DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 High incidence of sepsis and bloodstream infections
    • 4.2.1.2 Growing adoption of rapid molecular and syndromic diagnostics
    • 4.2.1.3 Increasing focus on antimicrobial stewardship and expansion of biomarker-based testing for early sepsis detection and risk assessment
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High cost of advanced molecular diagnostic platforms
    • 4.2.2.2 Limited reimbursement for novel sepsis diagnostic technologies
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 AI-enabled sepsis diagnosis and clinical decision support
    • 4.2.3.2 Development of next-generation host-response biomarkers
    • 4.2.3.3 Growth of rapid POC and decentralized testing
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Clinical complexity and heterogeneous presentation of sepsis
• 4.3 UNMET NEEDS & WHITE SPACES
  • 4.3.1 UNMET NEEDS IN SEPSIS DIAGNOSTICS MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
  • 4.5.1 KEY MOVES & STRATEGIC FOCUS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 BARGAINING POWER OF SUPPLIERS
  • 5.1.2 BARGAINING POWER OF BUYERS
  • 5.1.3 THREAT OF NEW ENTRANTS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL SEPSIS DIAGNOSTICS INDUSTRY
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
  • 5.5.1 SEPSIS DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024-2026
  • 5.6.2 AVERAGE SELLING PRICE TREND, BY REGION, 2024-2026
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT SCENARIO (HS CODE 3822)
  • 5.7.2 EXPORT SCENARIO (HS CODE 3822)
• 5.8 KEY CONFERENCES & EVENTS, 2026-2027
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.10 INVESTMENT & FUNDING SCENARIO
• 5.11 IMPACT OF US TARIFFS-SEPSIS DIAGNOSTICS MARKET
  • 5.11.1 INTRODUCTION
  • 5.11.2 KEY TARIFF RATES
  • 5.11.3 PRICE IMPACT ANALYSIS
  • 5.11.4 IMPACT ON REGIONS
    • 5.11.4.1 North America
    • 5.11.4.2 Europe
    • 5.11.4.3 Asia Pacific
  • 5.11.5 IMPACT ON END-USE INDUSTRIES
    • 5.11.5.1 Hospital and specialty clinics
    • 5.11.5.2 Pathology and reference laboratories
    • 5.11.5.3 Research laboratories, academic institutes, and CROs

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 HOST-RESPONSE DIAGNOSTICS (TRANSCRIPTOMICS & IMMUNE PROFILING)
  • 6.1.2 AI-ENABLED AND PREDICTIVE SEPSIS DIAGNOSTICS
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING (RAPID AST)
  • 6.2.2 NEXT-GENERATION SEQUENCING (NGS) AND METAGENOMIC SEQUENCING
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 CONTINUOUS PATIENT MONITORING & CLINICAL DECISION SUPPORT SYSTEMS (CDSS)
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
• 6.5 PATENT ANALYSIS
  • 6.5.1 LIST OF MAJOR PATENTS
• 6.6 FUTURE APPLICATIONS
• 6.7 IMPACT OF AI/GENERATIVE AI ON SEPSIS DIAGNOSTICS MARKET
  • 6.7.1 INTRODUCTION
  • 6.7.2 TOP USE CASES & MARKET POTENTIAL
  • 6.7.3 KEY COMPANIES IMPLEMENTING AI
  • 6.7.4 FUTURE OF AI

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY ANALYSIS
    • 7.1.1.1 North America
      • 7.1.1.1.1 US
      • 7.1.1.1.2 Canada
    • 7.1.1.2 Europe
      • 7.1.1.2.1 Germany
      • 7.1.1.2.2 UK
      • 7.1.1.2.3 France
      • 7.1.1.2.4 Italy
    • 7.1.1.3 Asia Pacific
      • 7.1.1.3.1 China
      • 7.1.1.3.2 Japan
      • 7.1.1.3.3 India
      • 7.1.1.3.4 Australia
    • 7.1.1.4 Latin America
      • 7.1.1.4.1 Brazil
      • 7.1.1.4.2 Mexico
    • 7.1.1.5 Middle East
      • 7.1.1.5.1 Africa
  • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 7.2 SUSTAINABILITY INITIATIVES
  • 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
    • 7.2.1.1 Eco-friendly initiatives
  • 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY
• 8.6 REVENUE POTENTIAL
  • 8.6.1 COST DYNAMICS

9 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 BLOOD CULTURE MEDIA
  • 9.2.1 CONTINUED RELIANCE ON BLOOD CULTURE AS GOLD STANDARD FOR BLOODSTREAM INFECTION DIAGNOSIS SUSTAINS DEMAND
• 9.3 ASSAYS & REAGENT KITS
  • 9.3.1 INCREASING ADOPTION OF RAPID MOLECULAR AND BIOMARKER-BASED TESTING DRIVES RECURRING DEMAND FOR ASSAYS AND REAGENT KITS
• 9.4 INSTRUMENTS
  • 9.4.1 EXPANSION OF LAB AUTOMATION AND RAPID DIAGNOSTIC PLATFORMS ACCELERATES INVESTMENT IN ADVANCED INSTRUMENTS
• 9.5 SOFTWARE
  • 9.5.1 IMPLEMENTATION OF LAB INFORMATICS AND ANTIMICROBIAL STEWARDSHIP SOLUTIONS SUPPORTS SOFTWARE ADOPTION

10 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY

• 10.1 INTRODUCTION
• 10.2 BLOOD CULTURE (MICROBIOLOGY TESTING)
  • 10.2.1 AS REGULATORY AND CLINICAL GOLD STANDARD, BLOOD CULTURE HOLDS LARGEST MARKET SHARE
• 10.3 IMMUNOASSAYS
  • 10.3.1 EXPANDING ADOPTION OF HOST-RESPONSE BIOMARKERS FOR EARLY SEPSIS ASSESSMENT AND ANTIMICROBIAL STEWARDSHIP DRIVES MARKET GROWTH
• 10.4 MOLECULAR DIAGNOSTICS
  • 10.4.1 PCR
    • 10.4.1.1 Widespread hospital adoption of syndromic multiplex panels for rapid pathogen and resistance gene identification to propel market growth
  • 10.4.2 MICROARRAYS
    • 10.4.2.1 Stable utilization in established blood culture identification workflows supports moderate growth
  • 10.4.3 FISH/PNA-FISH
    • 10.4.3.1 Retention of rapid Gram stain-adjunct testing in cost-constrained laboratories sustains low-growth utilization amid progressive substitution
  • 10.4.4 DNA SEQUENCING & NGS
    • 10.4.4.1 Growing clinical interest in culture-independent broad-spectrum pathogen detection drives adoption, constrained by cost and reimbursement barriers
  • 10.4.5 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
• 10.5 FLOW CYTOMETRY
  • 10.5.1 GROWING CLINICAL INTEREST IN CELLULAR HOST-RESPONSE BIOMARKERS FOR EARLY SEPSIS RISK ASSESSMENT SUPPORTS STEADY MARKET GROWTH
• 10.6 MASS SPECTROMETRY
  • 10.6.1 RISING EMPHASIS ON RAPID DIAGNOSTICS, LAB AUTOMATION, AND ANTIMICROBIAL STEWARDSHIP PROPELS ADOPTION
• 10.7 CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS
  • 10.7.1 WIDE UTILIZATION OF INFLAMMATORY BIOMARKERS AND RISING ADOPTION OF POC DIAGNOSTICS PROPEL MARKET GROWTH

11 SEPSIS DIAGNOSTICS MARKET, BY METHOD

• 11.1 INTRODUCTION
• 11.2 CONVENTIONAL DIAGNOSTICS
  • 11.2.1 RELIANCE ON MANUAL MICROBIOLOGICAL AND BIOCHEMICAL WORKFLOWS IN RESOURCE-CONSTRAINED AND LOW-THROUGHPUT SETTINGS SUSTAINS DEMAND
• 11.3 AUTOMATED DIAGNOSTICS
  • 11.3.1 GROWING INSTALLATION OF AUTOMATED PLATFORMS TO EXPEDITE TIME-TO-RESULT AND ADDRESS STAFFING SHORTAGES DRIVES SEGMENT GROWTH

12 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE

• 12.1 INTRODUCTION
• 12.2 BACTERIAL SEPSIS
  • 12.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS
    • 12.2.1.1 Rising prevalence of carbapenem-resistant and ESBL-producing organisms driving demand for resistance-marker testing
  • 12.2.2 GRAM-POSITIVE BACTERIAL SEPSIS
    • 12.2.2.1 Established diagnostic workflows for staphylococcal and enterococcal bloodstream infection sustain stable growth
• 12.3 FUNGAL SEPSIS
  • 12.3.1 RISING INCIDENCE OF FUNGAL BLOODSTREAM INFECTIONS DRIVES DEMAND
• 12.4 OTHER PATHOGEN TYPES

13 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE

• 13.1 INTRODUCTION
• 13.2 LABORATORY TESTS
  • 13.2.1 CENTRALIZATION OF BLOOD CULTURE, MOLECULAR, AND MASS SPECTROMETRY WORKFLOWS WITHIN ACCREDITED HOSPITAL LABORATORIES SUSTAINS THE DOMINANT SHARE
• 13.3 POC TESTS
  • 13.3.1 EXPANDING NEAR-PATIENT LACTATE AND BIOMARKER TESTING TO MEET SEPSIS BUNDLE COMPLIANCE TIMELINES DRIVES GROWTH

14 SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE

• 14.1 INTRODUCTION
• 14.2 WHOLE BLOOD
  • 14.2.1 EMERGENCE OF DIRECT-FROM-BLOOD MOLECULAR TESTING AND WIDESPREAD USAGE OF WHOLE BLOOD SPECIMENS DRIVE MARKET
• 14.3 SERUM
  • 14.3.1 SUSTAINED RELIANCE ON SERUM AND PLASMA FOR BIOMARKER-BASED TRIAGE AND ANTIBIOTIC STEWARDSHIP MAINTAINS STABLE GROWTH

15 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY

• 15.1 INTRODUCTION
• 15.2 SINGLEPLEX
  • 15.2.1 RECURRING VOLUME OF SINGLE-ANALYTE BIOMARKER AND CHEMISTRY TESTING SUSTAINS MARKET SHARE
• 15.3 MULTIPLEX
  • 15.3.1 WIDESPREAD ADOPTION OF SYNDROMIC PANELS DELIVERING SIMULTANEOUS PATHOGEN AND RESISTANCE GENE IDENTIFICATION DRIVES GROWTH

16 SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY

• 16.1 INTRODUCTION
• 16.2 SEPSIS DIAGNOSIS
  • 16.2.1 EXPANDING AVAILABILITY OF ASSAYS AND WIDESPREAD TESTING TO DRIVE MARKET
• 16.3 PATHOGEN IDENTIFICATION
  • 16.3.1 ENTRENCHED CULTURE AND IDENTIFICATION WORKFLOWS SUSTAIN SUBSTANTIAL VOLUME
• 16.4 SEPSIS RISK STRATIFICATION
  • 16.4.1 RISING DEPLOYMENT OF AUTOMATED SEVERITY SCORING AND CELLULAR HOST-RESPONSE MARKERS INTEGRATED WITH EARLY WARNING SYSTEMS DRIVES HIGH GROWTH
• 16.5 ANTIMICROBIAL STEWARDSHIP SUPPORT
  • 16.5.1 INSTITUTIONAL REQUIREMENT FOR STEWARDSHIP AND ESCALATING BURDEN OF ANTIMICROBIAL RESISTANCE TO DRIVE MARKET
• 16.6 PROGNOSIS & OUTCOME PREDICTION
  • 16.6.1 LIMITED UTILITY OF PROGNOSTIC INFORMATION CONTINUES TO HINDER DEDICATED ADOPTION

17 SEPSIS DIAGNOSTICS MARKET, BY END USER

• 17.1 INTRODUCTION
• 17.2 HOSPITALS & SPECIALTY CLINICS
  • 17.2.1 INCREASING BURDEN OF SEPSIS AND GROWING ADOPTION OF RAPID DIAGNOSTIC WORKFLOWS IN ACUTE CARE SETTINGS TO DRIVE MARKET LEADERSHIP
• 17.3 PATHOLOGY & REFERENCE LABORATORIES
  • 17.3.1 INCREASING OUTSOURCING OF SPECIALIZED MICROBIOLOGY AND MOLECULAR TESTING SUPPORTS STEADY MARKET GROWTH
• 17.4 RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS
  • 17.4.1 EXPANDING SEPSIS BIOMARKER RESEARCH AND DIAGNOSTIC INNOVATION CONTINUE TO SUPPORT LONG-TERM MARKET DEVELOPMENT

18 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION, (NUMBER OF TESTS IN MILLIONS)

• 18.1 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION, (NUMBER OF TESTS IN MILLIONS)

19 SEPSIS DIAGNOSTICS MARKET, BY REGION

• 19.1 INTRODUCTION
• 19.2 NORTH AMERICA
  • 19.2.1 US
    • 19.2.1.1 High burden of sepsis and early adoption of advanced diagnostic technologies drive market leadership
  • 19.2.2 CANADA
    • 19.2.2.1 Strong public healthcare infrastructure and expanding adoption of advanced microbiology technologies support market growth
• 19.3 EUROPE
  • 19.3.1 GERMANY
    • 19.3.1.1 Advanced clinical microbiology infrastructure and strong laboratory automation drive market leadership
  • 19.3.2 UK
    • 19.3.2.1 National sepsis initiatives and NHS investments continue to accelerate adoption of rapid diagnostics
  • 19.3.3 FRANCE
    • 19.3.3.1 Expansion of hospital microbiology networks and leadership of domestic diagnostic manufacturers drive growth
  • 19.3.4 ITALY
    • 19.3.4.1 Growing burden of HAIs supports adoption of advanced sepsis diagnostics
  • 19.3.5 SWITZERLAND
    • 19.3.5.1 Presence of global diagnostic manufacturers and strong healthcare investment support market growth
  • 19.3.6 SPAIN
    • 19.3.6.1 Increasing healthcare modernization and laboratory automation continue to strengthen market growth
  • 19.3.7 REST OF EUROPE
• 19.4 ASIA PACIFIC
  • 19.4.1 CHINA
    • 19.4.1.1 Rapid healthcare modernization and expanding hospital laboratory infrastructure drive market growth
  • 19.4.2 JAPAN
    • 19.4.2.1 Advanced healthcare infrastructure and high adoption of innovative diagnostics support market expansion
  • 19.4.3 INDIA
    • 19.4.3.1 Expanding healthcare infrastructure and rising sepsis burden accelerate adoption of advanced diagnostics
  • 19.4.4 SOUTH KOREA
    • 19.4.4.1 Government investment in precision medicine and diagnostic innovation drives market expansion
  • 19.4.5 AUSTRALIA
    • 19.4.5.1 Strong clinical guidelines and high adoption of laboratory automation support market growth
  • 19.4.6 REST OF ASIA PACIFIC
• 19.5 LATIN AMERICA
  • 19.5.1 BRAZIL
    • 19.5.1.1 Growing burden of infectious diseases and expansion of hospital laboratory infrastructure drive market growth
  • 19.5.2 MEXICO
    • 19.5.2.1 Healthcare modernization and expanding access to advanced diagnostics support market growth
  • 19.5.3 REST OF LATIN AMERICA
• 19.6 MIDDLE EAST & AFRICA
  • 19.6.1 GCC COUNTRIES
    • 19.6.1.1 Healthcare modernization and government investments in advanced diagnostics drive regional growth
  • 19.6.2 REST OF MIDDLE EAST & AFRICA

20 COMPETITIVE LANDSCAPE

• 20.1 INTRODUCTION
• 20.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 20.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN SEPSIS DIAGNOSTICS MARKET
• 20.3 REVENUE ANALYSIS, 2023-2025
• 20.4 MARKET SHARE ANALYSIS, 2025
  • 20.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
• 20.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 20.5.1 STARS
  • 20.5.2 EMERGING LEADERS
  • 20.5.3 PERVASIVE PLAYERS
  • 20.5.4 PARTICIPANTS
  • 20.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 20.5.5.1 Company footprint
    • 20.5.5.2 Region footprint
    • 20.5.5.3 Product footprint
    • 20.5.5.4 Technology footprint
    • 20.5.5.5 Pathogen type footprint
    • 20.5.5.6 Test type footprint
    • 20.5.5.7 Method footprint
• 20.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 20.6.1 PROGRESSIVE COMPANIES
  • 20.6.2 RESPONSIVE COMPANIES
  • 20.6.3 DYNAMIC COMPANIES
  • 20.6.4 STARTING BLOCKS
  • 20.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 20.6.5.1 Detailed list of key startups/SMEs
    • 20.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
    • 20.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
• 20.7 COMPANY VALUATION & FINANCIAL METRICS
  • 20.7.1 FINANCIAL METRICS
  • 20.7.2 COMPANY VALUATION
• 20.8 BRAND/PRODUCT COMPARISON
• 20.9 COMPETITIVE SCENARIO
  • 20.9.1 PRODUCT LAUNCHES & APPROVALS
  • 20.9.2 DEALS
  • 20.9.3 OTHER DEVELOPMENTS

21 COMPANY PROFILES

• 21.1 KEY PLAYERS
  • 21.1.1 BIOMERIEUX
    • 21.1.1.1 Business overview
    • 21.1.1.2 Products offered
    • 21.1.1.3 Recent developments
      • 21.1.1.3.1 Product launches & approvals
      • 21.1.1.3.2 Deals
      • 21.1.1.3.3 Other developments
    • 21.1.1.4 MnM view
      • 21.1.1.4.1 Key strengths
      • 21.1.1.4.2 Strategic choices
      • 21.1.1.4.3 Weaknesses & competitive threats
  • 21.1.2 BECTON, DICKINSON AND COMPANY (BD)
    • 21.1.2.1 Business overview
    • 21.1.2.2 Products offered
    • 21.1.2.3 Recent developments
      • 21.1.2.3.1 Product launches & approvals
      • 21.1.2.3.2 Deals
      • 21.1.2.3.3 Other developments
    • 21.1.2.4 MnM view
      • 21.1.2.4.1 Key strengths
      • 21.1.2.4.2 Strategic choices
      • 21.1.2.4.3 Weaknesses and competitive threats
  • 21.1.3 DANAHER
    • 21.1.3.1 Business overview
    • 21.1.3.2 Products offered
    • 21.1.3.3 Recent developments
      • 21.1.3.3.1 Deals
    • 21.1.3.4 MnM view
      • 21.1.3.4.1 Key strengths
      • 21.1.3.4.2 Strategic choices
      • 21.1.3.4.3 Weaknesses & competitive threats
  • 21.1.4 DIASORIN S.P.A.
    • 21.1.4.1 Business overview
    • 21.1.4.2 Products offered
    • 21.1.4.3 Recent developments
      • 21.1.4.3.1 Product launches & approvals
    • 21.1.4.4 MnM view
      • 21.1.4.4.1 Key strengths
      • 21.1.4.4.2 Strategic choices
      • 21.1.4.4.3 Weaknesses & competitive threats
  • 21.1.5 F. HOFFMANN-LA ROCHE LTD.
    • 21.1.5.1 Business overview
    • 21.1.5.2 Products offered
    • 21.1.5.3 Recent developments
      • 21.1.5.3.1 Product launches & approvals
    • 21.1.5.4 MnM view
      • 21.1.5.4.1 Key strengths
      • 21.1.5.4.2 Strategic choices
      • 21.1.5.4.3 Weaknesses & competitive threats
  • 21.1.6 THERMO FISHER SCIENTIFIC INC.
    • 21.1.6.1 Business overview
    • 21.1.6.2 Products offered
  • 21.1.7 BRUKER CORPORATION
    • 21.1.7.1 Business overview
    • 21.1.7.2 Products offered
    • 21.1.7.3 Recent developments
      • 21.1.7.3.1 Product launches & approvals
      • 21.1.7.3.2 Other developments
  • 21.1.8 ABBOTT
    • 21.1.8.1 Business overview
    • 21.1.8.2 Products offered
  • 21.1.9 SYSMEX CORPORATION
    • 21.1.9.1 Business overview
    • 21.1.9.2 Products offered
    • 21.1.9.3 Recent developments
      • 21.1.9.3.1 Deals
  • 21.1.10 SIEMENS HEALTHINEERS AG
    • 21.1.10.1 Business overview
    • 21.1.10.2 Products offered
  • 21.1.11 QIAGEN
    • 21.1.11.1 Business overview
    • 21.1.11.2 Products offered
    • 21.1.11.3 Recent developments
      • 21.1.11.3.1 Product launches & approvals
  • 21.1.12 SEEGENE INC.
    • 21.1.12.1 Business overview
    • 21.1.12.2 Products offered
    • 21.1.12.3 Recent developments
      • 21.1.12.3.1 Product launches & approvals
  • 21.1.13 PHC HOLDINGS CORPORATION
    • 21.1.13.1 Business overview
    • 21.1.13.2 Products offered
  • 21.1.14 QUIDELORTHO CORPORATION
    • 21.1.14.1 Business overview
    • 21.1.14.2 Products offered
  • 21.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • 21.1.15.1 Business overview
    • 21.1.15.2 Products offered
• 21.2 OTHER PLAYERS
  • 21.2.1 EKF DIAGNOSTICS HOLDINGS PLC
  • 21.2.2 INFLAMMATIX, INC.
  • 21.2.3 BODITECH MED INC
  • 21.2.4 ALIFAX S.R.L.
  • 21.2.5 ADVANDX (OPGEN)
  • 21.2.6 FUJIREBIO
  • 21.2.7 IMMUNEXPRESS
  • 21.2.8 RESPONSE BIOMEDICAL CORPORATION
  • 21.2.9 DEEPULL DIAGNOSTICS S.L.
  • 21.2.10 SEKISUI DIAGNOSTICS

22 RESEARCH METHODOLOGY

• 22.1 RESEARCH DATA
• 22.2 SECONDARY DATA
  • 22.2.1 LIST OF SECONDARY SOURCES
  • 22.2.2 KEY DATA FROM SECONDARY SOURCES
  • 22.2.3 PRIMARY DATA
    • 22.2.3.1 List of primary sources
    • 22.2.3.2 Key data from primary sources
    • 22.2.3.3 Key industry insights
    • 22.2.3.4 Breakdown of primary interviews
• 22.3 MARKET SIZE ESTIMATION
  • 22.3.1 TOTAL MARKET SIZE: SEPSIS DIAGNOSTICS MARKET
  • 22.3.2 BOTTOM-UP APPROACH
    • 22.3.2.1 Approach 1: Revenue estimation of key players
    • 22.3.2.2 Approach 2: Study of annual reports and investor presentations
    • 22.3.2.3 Approach 3: Primary interviews
    • 22.3.2.4 Growth forecast
    • 22.3.2.5 CAGR projections
  • 22.3.3 TOP-DOWN APPROACH
• 22.4 DATA TRIANGULATION
• 22.5 RESEARCH ASSUMPTIONS
  • 22.5.1 STUDY ASSUMPTIONS
  • 22.5.2 PARAMETRIC ASSUMPTIONS
  • 22.5.3 GROWTH RATE ASSUMPTIONS
• 22.6 RESEARCH LIMITATIONS
• 22.7 RISK ASSESSMENT

23 APPENDIX

• 23.1 DISCUSSION GUIDE
• 23.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 23.3 CUSTOMIZATION OPTIONS
• 23.4 RELATED REPORTS
• 23.5 AUTHOR DETAILS